DrugOn: A Comprehensive Drug Ontology for Precision Oncology

Kevin Kornrumpf,Vera Gnaß,Myrine Holm,Tim Beißbarth,Raphael Koch,Jürgen Dönitz

DOI: https://doi.org/10.1101/2024.09.23.24314201

2024-09-24

Abstract:Introduction: Precision oncology and biomedical cancer research increasingly rely on tools to select optimal drugs targeting specific genetic alterations in cancer. A major challenge for bioinformatic tools supporting drug selection is to standardize different annotations (substance, drug name, drug class) to a common level, typically the drug class. While manual classification is time-consuming and potentially biased, existing resources often lack completeness, granularity, or mix up drug classes and drug targets. A structured, automatically built drug ontology such as DrugOn fills these gaps, improving decision support and data-driven research. Methods: DrugOn integrates information from multiple sources to create a comprehensive drug ontology. It includes categories, molecular targets and additional annotations from DrugBank, ATC, MesH, KEGG and ClueIO. The combination of this data enables accurate identification of drug categories for each drug. Results: DrugOn's effectiveness was demonstrated by classifying 336 drugs from CIViC. It agreed with manually curated database-derived classifications for 268 out of 282 drugs assessed in translational lymphoma research. In 54 cases, classification was not possible due to data gaps. DrugOn provides a REST API and a front-end application for ontology exploration and automated drug queries. Conclusion: DrugOn, a unified drug ontology, is derived from public datasets and refined by precise processing rules to ensure a reliable, updatable resource for drug information, in precision medicine. It uniquely categorizes drug classes and target proteins, and its structured format, complemented by an accessible API, allows for easy integration into data driven pipelines. Initially tailored for lymphoma research, DrugOn's adaptable nature supports broader cancer research applications and potential data source expansions. DrugOn is accessible at https://mtb.bioinf.med.uni-goettingen.de/drugon-web.

Pharmacology and Therapeutics

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to effectively select the best drugs for specific gene alterations in precision oncology and biomedical cancer research. Specifically, the author points out that the main challenge currently faced by bioinformatics tools that support drug selection is to standardize different annotations (such as substances, drug names, drug classes) to a common level, usually the drug class. Manual classification is time - consuming and may be biased, and existing resources often lack completeness, detail, or confuse drug classes and drug targets.

To solve these problems, the author has developed a comprehensive drug ontology, DrugOn, which aims to fill the gaps in existing resources and improve decision - support and data - driven research. DrugOn creates a structured, automatically - constructed drug ontology by integrating information from multiple sources, thereby improving the accuracy and consistency of drug classification.

### Key issue summary:
1. **Standardize drug annotations**: Standardize drug information from different sources (such as substances, drug names, drug classes) to a common level.
2. **Improve classification accuracy**: Reduce the time consumption and potential bias of manual classification and provide more accurate drug classification.
3. **Integrate multi - source data**: Integrate multiple database resources (such as DrugBank, ATC, MeSH, KEGG, and ClueIO) to ensure the completeness and detail of drug information.
4. **Support precision medicine**: Provide reliable data support for precision oncology and biomedical cancer research to help select the best treatment options.

Through these improvements, DrugOn provides a more efficient, accurate, and reliable solution for drug information management, especially suitable for research and clinical scenarios that require rapid access to and processing of large amounts of drug data.